A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors

Update Il y a 4 ans
Reference: NCT01724320

Woman and Man

Extract

The purpose of this study is to determine the recommended dose (RD) for further phase II studies, of the Galectin-1 inhibitor OTX008 given subcutaneously in patients with advanced solid tumors


Inclusion criteria

  • Solid Tumors

Links